Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wild-type iNK
- Development stage
- Preclinical
- Lead developer
- Cell Inspire Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Wild-type iNK (WT iNK) refers to natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) that have not undergone genetic modification to express chimeric antigen receptors (CARs). These cells serve as an allogeneic, off-the-shelf cell therapy platform. Developed by companies such as Cell Inspire Biotechnology, WT iNK cells possess innate anti-tumor activity mediated by natural activating receptors, including NKG2D, NKp30, and CD16 (FcγRIIIa). In preclinical studies for hematologic malignancies like multiple myeloma, WT iNK cells are utilized both as a standalone therapeutic candidate and as a baseline control to benchmark the enhanced potency of CAR-engineered iNK variants.
- Other names
- wild-type iPSC-derived natural killer cellsWT-iNK
02
Targets
NKG2D–H60 (Killer cell lectin-like receptor subfamily K member 1 (NKG2D)–Histocompatibility 60 (H60) interaction)NKp30 (Natural cytotoxicity triggering receptor 3 (NCR3))Killer cell lectin-like receptor subfamily K member 1–Retinoic acid early transcript 1 interactionFc gamma receptor III (CD16)–Immunoglobulin G fragment crystallizable (IgG Fc) interactionCD226 (DNAX accessory molecule 1)CD244–CD48 (Cluster of differentiation 244–Cluster of differentiation 48 interaction)
Beyond the preview
Go deeper on wild-type iNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wild-type iNK.